The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect.
The FDA is slated to reveal whether Eli Lilly’s supply of its obesity drug Zepbound can meet U.S. demand.
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
The FDA is slated to reveal whether Eli Lilly’s supply of its obesity drug Zepbound can meet U.S. demand.